1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J; Xu, R; Xuan, C; Xuan, L; Yan, W | 1 |
| Kraemer, R; Mullane, KM; Westlin, W | 1 |
1 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cardiomyopathies
| Article | Year |
|---|---|
Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion.
Topics: Arachidonic Acid; Arachidonic Acids; Blood Platelets; Cardiomyopathies; Coronary Disease; Eicosanoic Acids; Free Radicals; Humans; Lipoxygenase; Neutrophils; Oxygen; Platelet Activating Factor; Platelet Aggregation; Serotonin; SRS-A; Superoxides | 1988 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cardiomyopathies
| Article | Year |
|---|---|
BN52021 protects rat cardiomyocyte from doxorubicin induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cardiomyopathies; Cardiotoxicity; Cell Line; Cell Survival; Doxorubicin; Ginkgolides; In Situ Nick-End Labeling; Myocytes, Cardiac; Platelet Activating Factor; Rats | 2015 |